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Abstract
Cytomegalovirus (CMV) IgM indicates recent active CMV infection. CMV IgM seroprevalence
is a useful marker for prevalence of transmission. Using data from the National Health and
Nutrition Examination Survey (NHANES) III 1988–1994, we present estimates of CMV IgM
prevalence by race/ethnicity, provide a comparison of IgM seroprevalence among all women
and among CMV IgG positive women, and explore factors possibly associated with IgM sero-
prevalence, including socioeconomic status and exposure to young children. There was no
difference in IgM seroprevalence by race/ethnicity among all women (3.1%, 2.2%, and 1.6%
for non-Hispanic white, non-Hispanic black and Mexican American, respectively; P = 0.11).
CMV IgM seroprevalence decreased significantly with increasing age in non-Hispanic black
women (P<0.001 for trend) andmarginally among Mexican American women (P = 0.07),
while no apparent trend with age was seen in non-Hispanic white women (P = 0.99). Among
4001 IgG+ women, 118 were IgM+, resulting in 4.9% IgM seroprevalence. In IgG+ women,
IgM seroprevalence varied significantly by age (5.3%, 7.3%, and 3.7% for women of 12–19,
20–29, and 30–49 years; P = 0.04) and race/ethnicity (6.1%, 2.7%, and 2.0% for non-Hispanic
white, non-Hispanic black, and Mexican American; P<0.001). The factors reported associated
with IgG seroprevalence were not associated with IgM seroprevalence. The patterns of CMV
IgM seroprevalence by age, race/ethnicity, and IgG serostatus may help understanding the
epidemiology of congenital CMV infection as a consequence of vertical transmission and are
useful for identifying target populations for intervention to reduce CMV transmission.
Introduction
Cytomegalovirus (CMV) is a common human viral pathogen that typically causes minimal, if
any, symptoms in immunocompetent individuals.[1] However, CMV infection can cause
severe outcomes and even death in immunocompromised individuals and infants infected in
utero.[2–4] Active CMV infection during pregnancy is the leading viral cause of birth defects
and developmental disabilities in developed countries.[2]
An individual develops lifetime CMV IgG seropositivity (IgG+) after primary infection (the
first infection in life), after which CMV establishes latency with intermittent reactivation.
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CMV IgG+ individuals can be reinfected with another strain of CMV. CMV IgM can be pro-
duced after primary infection and after non-primary infection (reactivation or reinfection).[5]
It typically is detectable for only a few months,[6] and indicates recent active CMV infection.
The transiency of IgM makes CMV IgM seroprevalence rates a useful marker for prevalence of
transmission in a population at the time of testing.
In the U.S., CMV IgM seroprevalence in the general population have been briefly described
among women aged 12–49 years from the National Health and Nutrition Examination Survey
(NHANES) III 1988–1994.[7] The lack of temporal changes in CMV IgG seroprevalence from
1988–1994 to 1999–2004 [8] suggests that the factors associated with CMV transmission have
remained fairly consistent over time and that findings on IgM seroprevalence from NHANES
III are still informative for understanding the epidemiology of acute CMV infection and risk of
transmission. We expand on the previous analysis of IgM seroprevalence among US women
[7] by presenting estimates by race/ethnicity and by re-categorized age groups. We also present
a comparison of IgM seropositivity by race/ethnicity and age among all women and among
CMV IgG positive women to investigate whether future assessments of IgM seropositivity
could be conducted using a less expensive, more streamlined approach. In addition, we explore
factors possibly associated with IgM seroprevalence, including those previously identified as
being associated with CMV IgG seroprevalence such as socioeconomic status and exposure to
young children.[5]
Materials and Methods
Publically accessible data on CMV IgG and IgM of NHANES III 1998–1994 were analyzed and
IgM was only tested on women aged 12–49 years of age while IgG data available for all
NHANES III participants.[9] NHANES III was conducted by the Centers for Disease Control
and Prevention from 1988 to 1994 and was a complex, stratified, multistage probability cluster
sample of the noninstitutionalized civilian of the United States. The detailed methodology and
response rates of NHANES III are publically accessible.[10] In contrast to a previously pub-
lished analysis of all female NHANES participants,[7] only women of three racial/ethnic
groups (non-Hispanic white, non-Hispanic black and Mexican American) were included in
the current analysis in order to provide estimates by racial/ethnic groups that were consistent
with previous analyses of CMV IgG seroprevalence.[5, 8] NHANES methods for serum sample
selection and laboratory testing for CMV IgG and IgM have been reported previously.[5, 7]
Age was categorized as 12–19, 20–29, and 30–49 years with varied intervals to ensure that
there were at least 5 individuals in each subgroup as fewer subjects were IgM+ in those aged
30 years. Nationally representative estimates of IgM seroprevalence were calculated using the
same modified weights as in the prior report [7] after accounting for the proportion of available
serum samples by age groups and race/ethnicity with SAS Survey Procedures (SAS Inc., Cary,
NC). Risk factors associated with CMV IgG seroprevalence such as socioeconomic status and
exposure to young children were categorized as reported previously [5] and examined for their
association with CMV IgM seroprevalence in all and CMV IgG+ women. Home exposure to
young children was defined as reporting having at least one child aged6 years at home.
Results
Among the 5714 women included in the analysis, approximately half were aged 30–49 years
(2695, 47.2%) and similar proportions were aged 12–19 years and 20–29 years (1445 and 1574,
25.3% and 27.6%, respectively). Non-Hispanic white, non-Hispanic black and Mexican Ameri-
can participants each represented about one third of the study population (1825, 2013, and
1876; 31.9%, 35.2% and 32.8%, respectively). The majority of participants were IgG+ (4001,
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70%). A total of 121 women were CMV IgM+ for an overall prevalence estimate of 2.8% [95%
confidence interval (CI): 2.1–3.6%] among these three racial/ethnic groups. Overall, CMV IgM
seroprevalence did not differ significantly by race/ethnicity (3.1%, 2.2%, and 1.6% for non-His-
panic white, non-Hispanic black and Mexican American, respectively; P = 0.11). When strati-
fied by age, there was no difference by race/ethnicity among women aged 12–19 years
(P = 0.38), but non-Hispanic white women had higher IgM seroprevalence compared to Mexi-
can American women at 20–29 years of age (4.5% vs. 1.8%, P = 0.02), and higher IgM seroprev-
alence compared to non-Hispanic black and Mexican American women at age of 30–49 years
(2.7% vs. 0.8% and 0.7% for non-Hispanic white, non-Hispanic black, and Mexican American,
respectively; P = 0.03 and 0.01). IgM seroprevalence marginally varied by age with the highest
IgM seroprevalence among those aged 20–29 years and lower seroprevalence among those
aged 12–19 or 30–49 years (4.1%, 2.4% and 2.4%, respectively; P = 0.05). The patterns of CMV
IgM seroprevalence with age differed by race/ethnicity. CMV IgM seroprevalence decreased
significantly with increasing age in non-Hispanic black women (P<0.001 for trend) and mar-
ginally among Mexican American women (P = 0.07), while no apparent trend with age was
seen in non-Hispanic white women (P = 0.99) (Fig 1, Panel A).
Among the 121 CMV IgM+ women, 118 (97.5%) were CMV IgG+ and three (2.5%) were
IgG-. Among the 4001 CMV IgG+ women, overall IgM seroprevalence was 4.9% (95% CI: 3.4–
6.4%), and CMV IgM seroprevalence varied significantly by race/ethnicity (6.1% vs. 2.7% and
2.0% for non-Hispanic white vs. non-Hispanic black and Mexican American, respectively;
P = 0.002 and 0.005). When stratified by age, there was no difference by race/ethnicity among
women aged 12–19 years (P = 0.58), but non-Hispanic white women had higher IgM seroprev-
alence than women of other two racial/ethnic groups at age of 20–29 years (9.7% vs. 3.8% and
2.3% for non-Hispanic white, non-Hispanic black, and Mexican American, respectively;
P = 0.01 and<0.001) and age of 30–49 years (4.9% vs. 0.9% and 0.8% for non-Hispanic white,
non-Hispanic black, and Mexican American, respectively; P = 0.003 and 0.001). IgM seroprev-
alence also varied significantly by age (5.3%, 7.3%, and 3.7% for women of 12–19, 20–29, and
30–49 years, respectively; P = 0.04) among IgG+ women. Similar to findings from the analysis
of CMV IgM among all women, there were significant patterns of decreasing IgM seropreva-
lence with age in non-Hispanic black and Mexican American women (P<0.001 and = 0.03,
respectively), while lack of trend among women of non-Hispanic white (P = 0.37) (Fig 1, Panel
B).
The factors previously reported as associated with CMV IgG seroprevalence [5] such as edu-
cation level, poverty level, insurance, family size, area of residence, census region, or having a
child6 years of age at home were not associated with IgM seroprevalence (Table 1). Marital
status was associated with IgM seroprevalence among all women aged20 years (4.5% vs.
2.2% for single vs. married women, P = 0.04); however this association was not statistically sig-
nificant when the analysis was restricted to IgG+ women (6.8% vs. 3.8%, P = 0.11). Association
between CMV IgM seroprevalence and sexual behaviors such as number of lifetime sex part-
ners and age at initiation of sexual activity, which were reported as being associated with IgG
seroprevalence,[11] could not be examined due to sparsity of the data (approximately 50–60%
missing values for these factors).
Discussion
Using data from NHANES III 1988–1994, we present estimates of CMV IgM seroprevalence
by race/ethnicity in U.S. women of reproductive age. As a result of excluding “other or
unknown” racial/ethnic groups, our analyses demonstrated a slightly lower rate in overall
CMV IgM seroprevalence than previously reported (2.8% vs. 3.0%).[7] This small difference in
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point estimate of CMV IgM seroprevalence does not change our overall understanding of
CMV IgM seroprevalence in the U.S. However, the estimates we present by age and racial/
Fig 1. Cytomegalovirus IgM seroprevalence among All Women (Panel A) and IgG+Women only (Panel B) by Age and Racial/ethnic Group, NHANES III,
1988–1994.
doi:10.1371/journal.pone.0151996.g001
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Table 1. Differences in CMV IgM Seroprevalence amongWomen Aged 12–49 Years by Selected Demographic Factors, NHANES III, 1988–1994.
All women IgG+ women
IgM+ Sample size Prevalence (95% CI) P value IgM+ Sample size Prevalence (95% CI) P value
Overall 121 5714 2.8 (2.1–3.6) NA 118 4001 4.9 (3.4–6.4) NA
Race/ethnicity 0.11 <0.001
Non-Hispanic white 52 1825 3.1 (2.0–4.1) 50 892 6.1 (3.8–8.3)
Non-Hispanic black 44 2013 2.2 (1.5–2.8) 43 1582 2.7 (1.9–3.5)
Mexican American 25 1876 1.6 (0.6–2.6) 25 1527 2.0 (0.8–3.2)
Age 0.05 0.04
12–19 years 37 1445 2.4 (1.1–3.6) 37 810 5.3 (2.4–8.2)
20–29 years 48 1574 4.1 (2.7–5.5) 46 1104 7.3 (4.7–9.9)
30–49 years 36 2695 2.4 (1.2–3.5) 35 2087 3.7 (1.8–5.7)
Household income level 0.29 0.48
High 17 990 2.0 (0.5–3.5) 17 516 4.5 (1.1–8.0)
Middle 54 2185 3.3 (2.4–4.2) 51 1468 5.4 (3.7–7.2)
Low 37 2070 2.7 (1.7–3.8) 37 1647 4.0 (2.4–5.5)
Education 0.27 0.78
Completed 11th grade or less 39 2057 3.9 (2.3–5.4) 36 1693 4.6 (2.2–6.9)
Completed high school 47 1850 3.1 (2.1–4.1) 47 1258 5.5 (3.7–7.2)
College or higher 34 1767 2.2 (0.9–3.5) 34 1018 4.7 (2.0–7.4)
Family size 0.19 0.09
1–2 38 1207 3.9 (1.8–6.1) 37 811 6.7 (3.1–10.2)
3–4 46 2452 2.5 (1.6–3.4) 45 1622 4.9 (3.1–6.7)
5+ 37 2055 2.0 (1.1–3.0) 36 1568 2.9 (1.5–4.3)
Insurance 0.74 0.88
Government 18 993 2.8 (0.4–5.2) 18 787 4.0 (0.6–7.4)
Private 79 3567 2.7 (1.8–3.7) 76 2263 5.1 (3.1–7.0)
Uninsured 24 1154 3.6 (1.5–5.7) 24 951 4.9 (2.0–7.9)
Area of residence 0.56 0.73
Urban 50 2875 2.5 (1.1–4.0) 50 2074 4.6 (1.9–7.3)
Non-urban 71 2839 3.1 (2.2–3.9) 68 1927 5.2 (3.6–6.7)
Census region 0.31 0.28
Northeast 18 609 3.6 (2.3–4.9) 17 373 7.5 (3.4–11.5)
Midwest 28 1104 3.0 (1.7–4.2) 27 691 5.3 (3.1–7.6)
South 48 2527 2.9 (1.1–4.6) 47 1850 4.5 (1.8–7.2)
West 27 1474 1.9 (0.9–2.9) 27 1087 3.4 (1.3–5.4)
Birthplace NA NA
United States 116 4656 3.0 (2.1–3.8) 113 3028 5.3 (3.7–6.9)
Mexico 3 836 0.3 (0.0–0.6) 3 784 0.3 (0.0–0.7)
Other country 2 208 2.2 (0.0–5.7) 2 177 2.9 (0.0–7.6)
Have child aged 6 years at home 0.79 0.96
Yes 47 2186 3.0 (1.8–4.2) 47 1694 4.9 (3.0–6.9)
No 74 3528 2.8 (1.8–3.7) 71 2307 4.9 (2.9–6.8)
Marital status* 0.04 0.11
Married 46 2713 2.2 (1.6–2.9) 44 1972 3.8 (2.4–5.2)
Single 38 1550 4.5 (1.7–7.4) 37 1214 6.8 (2.5–11.1)
NA: not applicable.
* in women aged 20 years only.
doi:10.1371/journal.pone.0151996.t001
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ethnic groups provide useful baseline reference values for future studies to monitor CMV rates
of transmission over time and assess the relative contribution of different factors to IgM sero-
prevalence. In contrast to the prior study on IgM seroprevalence, [7] we found IgM seropreva-
lence did differ across age groups when collapsing 30–49 year olds into a single age group.
Given that 98% of CMV IgM+ women were identified from among IgG+ individuals, future
analyses of IgM seroprevalence using NHANES data could be more efficiently conducted by
limiting the sample to CMV IgG+ subjects, as that would require testing of fewer participants.
An additional benefit of this approach is that variations in IgM seroprevalence would be less
likely to be diluted by the inclusion of IgG- participants, as evidenced by the significant differ-
ences by age and race/ethnicity observed in current analysis on IgG+ women only.
After primary infection, IgG seropositivity is lifelong and thus CMV IgG seroprevalence
reflects the accumulation of primary infections. In contrast, CMV IgM is produced transiently
as a result of primary infection and non-primary CMV infection (reinfection with a new strain
of CMV or reactivation of a latent strain), and, therefore, can be a marker of recent transmis-
sion. CMV IgG seroprevalence is relatively low among non-Hispanic whites. Because a greater
proportion are susceptible to primary infections, the higher rate of IgM positivity among white
females compared to non-Hispanic black and Mexican American women is not surprising.
Important sources for CMV transmission in adulthood are thought to include exposure to
young children and sexual activity.[11, 12] In our analysis, these factors were not associated
with IgM seropositivity, but this may reflect low statistical power due to the small number of
IgM positive participants as well as a dilution of the importance of these factors in face of the
combined contribution to overall IgM positivity from non-primary infections in addition to
primary infections, in contrast to the sole contribution to IgG positivity from primary infec-
tion. Differences in the patterns of IgM and IgG seroprevalence with age suggest non-primary
infection may account for a substantial proportion of IgM positivity, especially with increasing
age. While factors associated with CMV IgM seroprevalence among those undergoing primary
infection or reinfection may be similar to those associated with CMV IgG seroprevalence, fac-
tors associated with reactivation of latent infection may be very different. Understanding this
will be difficult until there are better tools for differentiating reinfection from reactivation. Fur-
ther study is needed to identify risk factors associated with reinfection and reactivation and to
determine the effectiveness of strategies to prevent infection, particularly during pregnancy.
Our finding of 2.8% IgM seroprevalence in U.S. women of reproductive age is similar to esti-
mates reported from other populations with moderate IgG seroprevalence such as France and
Japan (4.1% and 2.5%, respectively).[13, 14] In contrast, populations with higher CMV IgG
seroprevalence, such as Turkey and Korea (both above 98%), reported having much lower
prevalence of IgM in women (0.2% and 1.3%, respectively), and none of the IgM+ subjects in
those studies had low IgG avidity that would be suggestive of recent primary infection.[15, 16]
Variations in IgM seroprevalence had been observed in populations with high IgG seropreva-
lence such as India, China, and Brazil, where similar IgG seroprevalence (98.6%, 95.5%, and
96.4%, respectively) had been reported but IgM seroprevalence varies dramatically (0.07%,
0.5%, and 2.3%, respectively).[17–19] Populations with higher maternal CMV IgG seropreva-
lence generally have higher rates of congenital CMV infection than populations with moderate
IgG seroprevalence such as the U.S. [20, 21] The relative contributions of primary and non-pri-
mary maternal CMV infection to rates of congenital CMV infection across different popula-
tions are not well understood.
In summary, the patterns of CMV IgM seroprevalence differ by age and race/ethnicity in
women of reproductive age in the US, and the differences may be useful for understanding the
prevalence of transmission and congenital CMV epidemiology, therefore, potentially helpful in
identifying target population for effective prevention efforts to reduce CMV transmission, in
CMV IgM Seroprevalence in the US
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addition to providing baseline estimates for temporal monitoring on IgM seroprevalence over
time.
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